Intas Pharmaceuticals, through its wholly owned subsidiary Accord Healthcare, has completed the acquisition of Actavis UK & Actavis Ireland from Teva Pharmaceutical Industries, for an enterprise value of £603 million. The transaction is part of the European Commission’s anti-trust divestiture requirements arising from Teva’s acquisition of Actavis Generics.

Following this acquisition, Accord strengthens its footprint in the UK and Ireland retail market to become a leading player in the industry at European level, while Intas becomes a top 20 generic player globally.

Accord has always put relationships with customers and suppliers first, and will continue to do so, as work to unite Accord and Actavis UK and Ireland commences. Accord and Actavis UK and Ireland are committed to maintaining the high-standard of existing partnerships and continuing the strong relationships

Vänligen notera att:


The trade mark Actavis is used under licence by Teva Pharmaceuticals Europe B.V.